<DOC>
	<DOCNO>NCT01975363</DOCNO>
	<brief_summary>This randomize pilot clinical trial study nanoemulsion formulation curcumin reduce inflammatory change breast tissue obese woman high risk breast cancer . Curcumin may reduce inflammation breast tissue fat . This may affect risk develop breast cancer .</brief_summary>
	<brief_title>Pilot Study Curcumin Women With Obesity High Risk Breast Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : . ) To determine whether nanoemulsion curcumnin modulate pro-inflammatory biomarkers plasma breast adipose tissue . SECONDARY OBJECTIVES include : ii . ) To determine adherence , tolerability safety two dos nanoemulsion curcumin ( NEC ) woman high risk develop breast cancer ; iii . ) Evaluate possible correlation physical factor body mass index ( BMI ) , dietary intake pro-inflammatory effect plasma breast adipose tissue . iv . ) Explore additional biomarkers surrogate endpoint measure effect NEC . OUTLINE : Participants randomize 1 2 arm . ARM I : Participants receive low dose nanoemulsion curcumin orally ( PO ) twice daily ( BID ) 3 month . ARM II : Participants receive 100 mg nanoemulsion curcumin PO BID 3 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Carcinoma Situ</mesh_term>
	<mesh_term>Carcinoma , Ductal , Breast</mesh_term>
	<mesh_term>Carcinoma , Intraductal , Noninfiltrating</mesh_term>
	<mesh_term>Carcinoma , Lobular</mesh_term>
	<mesh_term>Curcumin</mesh_term>
	<criteria>INCLUSION CRITERIA : Increased risk breast cancer base family history , personal history Normal mammogram , clinical breast examination past 12 month &gt; 1 year pregnancy , lactation chemotherapy Body mass index ( BMI ) 25 40 EXCLUSION CRITERIA : Concurrent malignancy metastatic malignancy kind Ongoing chemotherapy , radiation therapy , cancerrelated treatment History bleeding tendency current use Coumadin anticoagulant Current previous history liver , gastrointestinal , hematopoietic , cardiac renal disease , viral , bacterial , atypical fungal infection organ system human immunodeficiency virus ( HIV ) infection Pregnant lactate woman Concurrent use hormonal contraception hormone replacement therapy Concurrent use immunosuppressant medication Concurrent use medication know inhibit induce hepatic enzyme cytochrome P450 ( CYP ) 3A4 Barriers fine needle aspiration sample breast adipose , include breast implant , history radiation breast , bilateral mastectomy , and/or insufficient breast adipose tissue adequate fine needle aspiration ( FNA ) sample Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , hypertension , psychiatric illness/social situation would limit compliance study requirement Chronic use herbal dietary supplement contain curcumin curcuminoids within 3 month prior entry study supplement might interact NEC Known sensitivity allergy turmeric spice curry Dietary intake large amount curry , turmeric spice black pepper regular basis Subjects stand regimen full dose aspirin ( &gt; = 325 mg/day ) , nonsteroidal antiinflammatory drug ( NSAID ) NSAIDcontaining product</criteria>
	<gender>Female</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Breast Cancer</keyword>
</DOC>